8-K/A: Vivos Therapeutics Pivots Strategy with Sleep Center Acquisition

Vivos Therapeutics completes the acquisition of The Sleep Center of Nevada, marking a strategic shift to a direct-to-patient model for obstructive sleep apnea treatment, while also detailing new management collaborations and associated risks.

Summary

• Vivos Therapeutics, Inc. (VVOS) completed the acquisition of R.D. Prabhu-Lata K. Shete MDs, LTD. d/b/a The Sleep Center of Nevada (SCN) on June 10, 2025.
• The acquisition involved a cash payment of $6.0 million, 607,287 shares of restricted common stock valued at $1.5 million, and the assumption of certain liabilities.
• A contingent earn-out of $1.5 million in restricted common stock is payable to Dr. Prabhu upon achievement of a financial milestone.
• Vivos's subsidiary, Airway Integrated Management Company, LLC (AIM), entered into 15-year Practice Administration Agreements (PAAs) with SCN and a newly formed entity, SCN PLLC, to manage their practices and ensure compliance with corporate practice of medicine laws.
• AIM will provide management and non-clinical services for monthly administration fees totaling $300,000 ($200,000 from SCN and $100,000 from SCN PLLC), subject to quarterly adjustments.
• Dr. Prabhu entered a Physician Employment Agreement with SCN, with an annual compensation of $400,000 plus bonus incentives and a board observation right.
• Vivos is implementing a new sales and marketing distribution model, pivoting to a direct-to-patient approach for its OSA treatment options, which is currently unproven.
• Operational planning for SCN integration began in April 2025, with two of SCN's seven locations already integrated on schedule and under budget.
• Patient demand for Vivos treatment options at SCN is currently exceeding capacity, with less than 40% of patients attempting to get appointments being processed.
• Vivos plans to deploy additional Sleep Optimization (SO) teams, with 1.5 teams currently deployed, two more expected in Q4 2025, and a fourth in Q1 2026, aiming for 4.5 teams by end of Q1 2026.
• Each fully functional SO team is estimated to potentially generate collections exceeding $500,000 per month, net of adjustments, with contribution margins above 50%.
• A revised management model for collaborations with sleep centers not interested in outright acquisition has been developed, where Vivos retains a supermajority controlling interest in a jointly owned management services entity.
• The first agreement under this revised model was signed on July 14, 2025, with MISleep Solution LLC in Auburn Hills, Michigan, with facilities estimated to open in October 2025.
• SCN reported revenues of $7.43 million in 2024 and $2.33 million for Q1 2025, with a net income of $0.73 million in 2024 and a net loss of $(0.21) million in Q1 2025 (due to a $250,000 settlement expense).
• Pro forma combined financial statements show a net loss of $(4.47) million for the three months ended March 31, 2025, and $(11.95) million for the year ended December 31, 2024, for Vivos and SCN combined.

Sentiment

Score: 5

Explanation: The filing presents a significant strategic pivot with potential for growth in a high-demand market, but it is heavily qualified by explicit risks, an 'unproven model,' and substantial debt. While patient demand is strong, operational capacity is currently a limiting factor. The Q1 2025 net loss for SCN due to a settlement also adds a cautious note. The sentiment is neutral, reflecting both the strategic upside and the considerable execution risks and financial obligations.

Positives

• The acquisition of SCN provides Vivos with direct access to patients for its FDA-cleared oral medical devices and adjunctive therapies, creating new, higher-margin revenue streams from diagnostic and consulting services.
• SCN's integration is proceeding on schedule and under budget for the initial two locations, demonstrating effective operational planning.
• Patient demand for Vivos treatment options at SCN is strong, currently exceeding capacity, indicating a robust market for their services.
• The estimated potential for each Sleep Optimization (SO) team to generate over $500,000 per month in net collections with contribution margins above 50% suggests high profitability for the new model.
• The development of a revised management model allows for growth through collaborations with other sleep centers, offering financial upside with limited capital expenditures and manageable risks compared to outright acquisitions.
• Vivos has an expanding pipeline of potential acquisition and management opportunities, driven by word-of-mouth, indicating strong interest in their model within the sleep medicine community.

Negatives

• The new sales, marketing, and distribution model, centered around acquiring and managing sleep centers, is explicitly stated as unproven, making future prospects difficult to evaluate.
• Vivos's prior collaboration with Rebis Health in 2024 did not meet expectations due to a lack of adequate control over operations, raising concerns about the effectiveness of collaboration models.
• Patient demand at SCN is currently exceeding capacity, with less than 40% of patients seeking appointments being processed, indicating a bottleneck in service delivery and potential lost revenue.
• There is an anticipated ramp-up period of up to 60 days for SO teams to become fully functional and up to five months or longer before net revenue collections match revenue-generating activity.
• SCN reported a net loss of $(206,845) for the three months ended March 31, 2025, primarily due to a $250,000 settlement expense, despite increased revenues.
• Vivos incurred substantial indebtedness, an $8.25 million Secured Promissory Note, to finance the SCN acquisition, which will require a portion of cash flow for debt servicing.

Risks

• The new sales and marketing distribution model is unproven and may not produce the anticipated benefits, making it difficult to evaluate future prospects and increasing investment risk.
• There is a material risk that the new model will not increase revenues or gross margins as anticipated, and Vivos may be unable to find additional sleep medical providers or derive intended benefits from acquisitions.
• Failure to implement and scale this marketing and distribution model would materially harm business, operating results, and likely cause stock price to suffer.
• Fluctuations, including declines, in the price of common stock could occur due to actual or anticipated fluctuations in financial results post-acquisition, changes in market expectations, competition, or competitor success.
• Substantial indebtedness incurred for the SCN acquisition ($8.25 million Secured Promissory Note) could adversely affect business, financial condition, and results of operations due to debt servicing costs.
• There is no assurance that Vivos's business, including SCN, will generate sufficient cash flow to service its indebtedness or fund other liquidity needs, potentially requiring debt restructuring, refinancing, or asset sales on unfavorable terms.
• Integrating SCN's operations may be more difficult, costly, or time-consuming than expected, leading to disruption of ongoing business, inconsistencies in standards, and loss of patients or employees.
• Contractual arrangements between AIM and SCN physicians may be found to constitute improper rendering of medical services or fee splitting under state Corporate Practice of Medicine (CPM) laws, leading to disciplinary action, penalties, and loss of revenue.
• Vivos may become a party to lawsuits, demands, claims, qui tam suits, governmental investigations, and audits (e.g., billing audits), which could result in substantial financial penalties, damage to reputation, or adverse effects on business operations.
• Changes in the structure of and payment rates under private insurance, Medicare, Medicaid, or other government programs could materially adversely affect business, results of operations, financial condition, and cash flows.
• Inability to recruit qualified talent and manage labor costs or shortages for labor-intensive operations (e.g., Sleep Optimization teams) could result in significant increases in operating costs, decreases in productivity, and disruptions in business operations.

Future Outlook

Vivos Therapeutics expects to recognize a small amount of SCN revenue during its fiscal second quarter (June 10-30, 2025), with a goal of increasing this revenue in the second half of 2025 and further in 2026. The company plans to strategically deploy additional personnel and resources, including two more Sleep Optimization (SO) teams in Q4 2025 and a fourth SO team in Q1 2026, to meet patient demand. Growth initiatives include expanding diagnostic and treatment services, establishing a pediatric OSA program, and collaborating with specialty medical groups. Lessons learned from SCN integration will be applied to future sleep center acquisitions or management collaborations. The new management model is expected to provide financial upside with limited capital expenditures and manageable risks, with the first facility under this model estimated to open in October 2025. Vivos anticipates its pipeline of potential acquisition and management opportunities will be a key driver of future accretive growth.

Management Comments

• Management believes two months of advance planning for SCN integration has benefited the process, allowing execution on schedule and under budget for two of SCN's seven locations.
• Management expects to recognize a small amount of SCN revenue during the fiscal second quarter (June 10-30, 2025), with a goal of increasing this revenue in the second half of 2025 and further in 2026.
• Management notes that patient demand is exceeding capacity to process and treat patients under the Vivos model, and the goal is to ramp up systems and operations to meet this demand.
• Management believes the current markets served by SCN could support up to eight SO teams, and potentially more with planned growth initiatives.
• Management identifies physical space, provider and staff recruiting/training, and third-party provider credentialing as limiting constraints for near-term revenue growth at SCN.
• Management believes the current expansion and relocation of facilities, coupled with additional SO team deployments, will help reduce the patient backlog, but full demand will not be met until additional teams are deployed in 2026.
• Management expects the economics of the Detroit SO team under the new management model to be similar to SCN's SO teams, with Vivos receiving a supermajority share of net profit distributions.
• Management believes the overall benefit of the new management model derives from limited risks and generally low equipment and facility capital expenditures relative to the potential revenue opportunity.

Industry Context

This announcement reflects a broader trend in healthcare towards integrated care models and direct-to-patient services, particularly in specialized fields like sleep medicine. By acquiring SCN and developing new management collaboration models, Vivos Therapeutics is moving beyond its traditional role as a medical device manufacturer to become a comprehensive provider of obstructive sleep apnea (OSA) diagnosis and treatment. This strategic pivot aims to capture a larger share of the value chain, address the growing demand for OSA solutions, and potentially differentiate itself in a competitive market by offering a full suite of services. The focus on expanding capacity and deploying specialized teams aligns with the need for efficient, scalable healthcare delivery in high-demand areas.

Comparison to Industry Standards

• The filing mentions a market of 'more than 2,600 American Academy of Sleep Medicine accredited sleep testing centers nationwide' as potential acquisition or management opportunities, indicating a fragmented market with significant consolidation potential. However, no specific comparable companies, projects, or results are detailed within the filing to assess Vivos's performance against industry benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Vivos's business model pivot, which includes acquisitions of sleep medical providers, may lead to future investigations and audits by governmental agencies, private civil qui tam complaints, and other lawsuits, demands, claims, legal proceedings, and/or other actions alleging non-compliance with applicable rules, regulations, laws, or the practice of medicine.
• There is a risk that contractual arrangements between AIM and SCN physicians could be found to constitute improper rendering of medical services or fee splitting under state Corporate Practice of Medicine (CPM) laws, potentially resulting in disciplinary action, penalties, damages, fines, and/or a loss of revenue.
• Any allegations against Vivos or the medical practices it manages could harm its reputation, stock price, and adversely affect relationships and contracts.

Related Party Transactions

• AIM, Vivos's wholly-owned subsidiary, entered into assignments and assumptions of three lease agreements previously held by SCN, where the landlords under these leases are entities managed by Dr. Prabhu, a shareholder of SCN and now an employed physician.

Stakeholder Impact

• Shareholders face potential for revenue growth and market expansion through the new direct-to-patient model, but also significant risks related to the unproven nature of the model, substantial debt, integration challenges, and potential regulatory scrutiny.
• Employees of SCN are integrated into Vivos's operations, and new Sleep Optimization teams are being hired, potentially creating new job opportunities and requiring extensive training.
• Customers (patients) of SCN and future managed practices will gain access to Vivos's advanced OSA treatment options, but may experience delays in receiving treatment due to current capacity constraints.
• Creditors, particularly Streeterville Capital, LLC, which provided the $8.25 million Secured Promissory Note, have increased exposure to Vivos's financial performance and its ability to service the new debt.
• Dr. Prabhu, as a former owner and now an employed physician, has a continued financial interest through his employment agreement and potential earn-out, as well as a board observation right, aligning his interests with Vivos's success.

Next Steps

• Continue to ramp up systems and operations at SCN by strategically deploying additional personnel and resources to meet patient demand.
• Deploy two additional Sleep Optimization (SO) teams during the fourth quarter of 2025.
• Deploy a fourth SO team sometime in the first quarter of 2026, aiming for a total of 4.5 SO teams operating by the end of Q1 2026.
• Expand diagnostic and treatment services at SCN locations.
• Establish and roll out a pediatric OSA program.
• Collaborate with certain specialty medical groups to treat patients with comorbid OSA.
• Apply lessons learned from SCN integration activities to future sleep center or medical practice acquisitions or management collaborations.
• Continue hiring, training, and onboarding one complete SO team for the Auburn Hills, Michigan facility, with an estimated opening date in October 2025.
• Pursue active discussions with a number of potential acquisition targets and management opportunities, including one currently under an exclusive letter of intent.

Key Dates

Recommendation

The filing details a significant strategic pivot for Vivos Therapeutics through the acquisition of The Sleep Center of Nevada and the implementation of a new direct-to-patient model. While this strategy offers substantial potential for revenue growth and market expansion in the high-demand OSA treatment sector, it is explicitly described as 'unproven' and carries numerous material risks. These include the challenges of integrating acquired operations, the substantial debt incurred for the acquisition, potential regulatory issues related to corporate practice of medicine laws, and the inherent difficulties in scaling a labor-intensive healthcare service. The prior collaboration with Rebis Health not meeting expectations further underscores execution risk. For existing investors, holding allows observation of the new model's performance and integration success. For potential new investors, a 'hold' stance is prudent until more concrete evidence of the model's effectiveness and successful mitigation of identified risks emerges, as the upside is balanced by significant uncertainties.

Keywords

Vivos Therapeutics, VVOS, Sleep Center of Nevada, SCN, Acquisition, Obstructive Sleep Apnea, OSA, Medical Devices, Healthcare, Practice Management, Corporate Practice of Medicine, SEC Filing, 8-K/A, Financial Reporting, Strategic Pivot, Debt Financing, Integration Risk, Sleep Optimization Teams